ES2731601T3 - Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo - Google Patents

Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo Download PDF

Info

Publication number: ES2731601T3
Authority: ES; Spain
Prior art keywords: dosage form; weight; solid dosage; methyl; hydrophilic binder
Prior art date: 2009-02-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES17181174T

Other languages

English (en)

Spanish (es)

Inventor

Jiang Zhang

Colin J Meyer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Reata Pharmaceuticals Inc

Original Assignee

Reata Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-13

Filing date

2010-02-12

Publication date

2019-11-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2731601(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-12 Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc

2019-11-18 Application granted granted Critical

2019-11-18 Publication of ES2731601T3 publication Critical patent/ES2731601T3/es

Status Active legal-status Critical Current

2030-02-12 Anticipated expiration legal-status Critical

Links

WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 title claims abstract description 63
239000000203 mixture Substances 0.000 title claims description 82
230000003111 delayed effect Effects 0.000 title description 2
239000011230 binding agent Substances 0.000 claims abstract description 46
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 32
239000002245 particle Substances 0.000 claims abstract description 25
239000007909 solid dosage form Substances 0.000 claims abstract description 18
229920002678 cellulose Polymers 0.000 claims abstract description 17
239000001913 cellulose Substances 0.000 claims abstract description 17
238000007496 glass forming Methods 0.000 claims abstract description 13
108010010803 Gelatin Proteins 0.000 claims abstract description 8
229920000159 gelatin Polymers 0.000 claims abstract description 8
235000019322 gelatine Nutrition 0.000 claims abstract description 8
235000011852 gelatine desserts Nutrition 0.000 claims abstract description 8
229920003063 hydroxymethyl cellulose Polymers 0.000 claims abstract description 8
229940031574 hydroxymethyl cellulose Drugs 0.000 claims abstract description 8
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 7
229920000881 Modified starch Polymers 0.000 claims abstract description 7
229920000642 polymer Polymers 0.000 claims abstract description 7
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 6
RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 claims abstract description 6
239000004215 Carbon black (E152) Substances 0.000 claims abstract description 6
229920002472 Starch Polymers 0.000 claims abstract description 6
229920006318 anionic polymer Polymers 0.000 claims abstract description 6
229920001519 homopolymer Polymers 0.000 claims abstract description 6
229930195733 hydrocarbon Natural products 0.000 claims abstract description 6
150000002430 hydrocarbons Chemical class 0.000 claims abstract description 6
239000008107 starch Substances 0.000 claims abstract description 6
235000019698 starch Nutrition 0.000 claims abstract description 6
229920001661 Chitosan Polymers 0.000 claims abstract description 5
239000008273 gelatin Substances 0.000 claims abstract description 5
230000009477 glass transition Effects 0.000 claims abstract description 5
229940086737 allyl sucrose Drugs 0.000 claims abstract description 4
239000002552 dosage form Substances 0.000 claims abstract description 4
238000009472 formulation Methods 0.000 claims description 64
239000007962 solid dispersion Substances 0.000 claims description 16
235000010980 cellulose Nutrition 0.000 claims description 15
238000000034 method Methods 0.000 claims description 15
238000001694 spray drying Methods 0.000 claims description 7
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 4
229920000609 methyl cellulose Polymers 0.000 claims description 4
239000001923 methylcellulose Substances 0.000 claims description 4
235000010981 methylcellulose Nutrition 0.000 claims description 4
239000001856 Ethyl cellulose Substances 0.000 claims description 3
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
235000019325 ethyl cellulose Nutrition 0.000 claims description 3
229920001249 ethyl cellulose Polymers 0.000 claims description 3
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
229940117841 methacrylic acid copolymer Drugs 0.000 claims description 3
-1 propylcellulose Polymers 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229920002301 cellulose acetate Polymers 0.000 claims description 2
235000015110 jellies Nutrition 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
239000003814 drug Substances 0.000 description 34
229940079593 drug Drugs 0.000 description 29
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 23
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 23
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 23
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 23
239000002775 capsule Substances 0.000 description 17
230000036470 plasma concentration Effects 0.000 description 16
239000000463 material Substances 0.000 description 14
238000010922 spray-dried dispersion Methods 0.000 description 11
238000004090 dissolution Methods 0.000 description 8
239000004480 active ingredient Substances 0.000 description 6
239000008187 granular material Substances 0.000 description 6
229920001531 copovidone Polymers 0.000 description 5
230000000694 effects Effects 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
241000282567 Macaca fascicularis Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
239000000523 sample Substances 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000009490 roller compaction Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
229920003134 Eudragit® polymer Polymers 0.000 description 2
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 2
101000652736 Homo sapiens Transgelin Proteins 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
102100031013 Transgelin Human genes 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
238000009513 drug distribution Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
238000000634 powder X-ray diffraction Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
TXGZJQLMVSIZEI-UQMAOPSPSA-N Bardoxolone Chemical compound C1=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5[C@H]4C(=O)C=C3[C@]21C TXGZJQLMVSIZEI-UQMAOPSPSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
229950002483 bardoxolone Drugs 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
238000009474 hot melt extrusion Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940071462 oralone Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000011164 primary particle Substances 0.000 description 1
108090000765 processed proteins & peptides Chemical class 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Chemical class 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES17181174T 2009-02-13 2010-02-12 Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo Active ES2731601T3 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US15260809P	2009-02-13	2009-02-13

Publications (1)

Publication Number	Publication Date
ES2731601T3 true ES2731601T3 (es)	2019-11-18

Family

ID=42335073

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES17181174T Active ES2731601T3 (es)	2009-02-13	2010-02-12	Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
ES10704298.8T Active ES2646816T3 (es)	2009-02-13	2010-02-12	Composiciones de dosificaciones orales de liberación retardada que contienen CDDO-Me amorfo

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES10704298.8T Active ES2646816T3 (es)	2009-02-13	2010-02-12	Composiciones de dosificaciones orales de liberación retardada que contienen CDDO-Me amorfo

Country Status (30)

Country	Link
US (2)	US8747901B2 (fr)
EP (2)	EP3254675B1 (fr)
JP (1)	JP5775464B2 (fr)
KR (2)	KR20140016441A (fr)
CN (2)	CN102387789A (fr)
AU (1)	AU2010213594B2 (fr)
BR (1)	BRPI1008023B8 (fr)
CA (1)	CA2752048C (fr)
CO (1)	CO6361904A2 (fr)
CY (2)	CY1119595T1 (fr)
DK (2)	DK2395979T3 (fr)
EA (1)	EA023652B1 (fr)
ES (2)	ES2731601T3 (fr)
HK (1)	HK1220130A1 (fr)
HR (2)	HRP20171639T1 (fr)
HU (2)	HUE035013T2 (fr)
IL (1)	IL214258A (fr)
LT (2)	LT3254675T (fr)
MX (1)	MX2011008344A (fr)
MY (1)	MY173715A (fr)
NO (1)	NO2395979T3 (fr)
NZ (1)	NZ594488A (fr)
PL (2)	PL3254675T3 (fr)
PT (2)	PT3254675T (fr)
SG (1)	SG173601A1 (fr)
SI (2)	SI2395979T1 (fr)
SM (2)	SMT201900432T1 (fr)
TR (1)	TR201909743T4 (fr)
WO (1)	WO2010093944A2 (fr)
ZA (1)	ZA201105630B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
ME03529B (fr)	2008-01-11	2020-04-20	Reata Pharmaceuticals Inc	Triterpénoïdes synthétiques et procédés d'utilisation dans le traitement de maladies
CA2721665C (fr)	2008-04-18	2017-01-24	Reata Pharmaceuticals, Inc.	Composes comprenant un pharmacore anti-inflammatoire et procedes d'utilisation
CN102083442B (zh)	2008-04-18	2014-08-13	里亚塔医药公司	抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
EP2279197B1 (fr)	2008-04-18	2014-11-05	Reata Pharmaceuticals, Inc.	Modulateurs d'inflammation antioxydants: dérivés d'acide oléanolique présentant une saturation dans l'anneau c
SI2271658T1 (sl)	2008-04-18	2017-03-31	Reata Pharmaceuticals, Inc.	Antioksidantni modulatorji vnetja: C-17 homologirani derivati oleanolne kisline
ES2449396T3 (es)	2008-07-22	2014-03-19	Trustees Of Dartmouth College	Cianoenonas monocíclicas y métodos de uso de las mismas
HUE035013T2 (en)	2009-02-13	2018-05-02	Reata Pharmaceuticals Inc	Delayed release, oral dosage compositions that contain amorphous cddo-me
EP2558105B1 (fr)	2010-04-12	2019-11-20	Reata Pharmaceuticals, Inc.	Bardoxolone methyl pour le traitement de l'obésité
CA2822071C (fr)	2010-12-17	2019-07-16	Reata Pharmaceuticals, Inc.	Pyrazolyl- et pyrimidinyl-enones tricycliques en tant que modulateurs d'inflammation antioxydants
HUE044081T2 (hu)	2011-03-11	2019-09-30	Reata Pharmaceuticals Inc	C4 Monometil-triterpenoid-származékok, és módszerek azok alkalmazására
CN103156861B (zh) *	2011-12-08	2015-11-25	陈丽梅	齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
BR112014026640B1 (pt)	2012-04-27	2021-05-18	Reata Pharmaceuticals, Inc	compostos derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimórficas, composição farmacêutica, e uso dos mesmos
US8981144B2 (en)	2012-05-08	2015-03-17	Trustees Of Dartmouth College	Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en)	2012-05-08	2014-12-30	Trustees Of Dartmouth College	Triterpenoids and compositions containing the same
US9556222B2 (en)	2012-06-15	2017-01-31	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
RS59194B1 (sr)	2012-09-10	2019-10-31	Reata Pharmaceuticals Inc	C17-alkandiilni i alkendiilni derivati oleanolne kiseline i metode za njihovu upotrebu
WO2014040073A1 (fr)	2012-09-10	2014-03-13	Reata Pharmaceuticals, Inc.	Dérivés c13-hydroxy de l'acide oléanolique et leurs procédés d'utilisation
AR096046A1 (es)	2013-04-24	2015-12-02	Abbvie Inc	Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
SG10201906113RA (en)	2013-08-23	2019-08-27	Reata Pharmaceuticals Inc	Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3212195A4 (fr)	2014-10-31	2018-06-06	The Regents of The University of California	Compositions et méthodes de traitement d'un dysfonctionnement cognitif associé au vih
US11059792B2 (en)	2015-02-12	2021-07-13	Reata Pharmaceuticals, Inc.	Imidazolyl tricyclic enones as antioxidant inflammation modulators
BR112018005861B1 (pt)	2015-09-23	2022-11-22	Reata Pharmaceuticals, Inc	Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos
CA3042123A1 (fr)	2016-11-08	2018-05-17	Reata Pharmaceuticals, Inc.	Methodes de traitement du syndrome d'alport a l'aide d'un methyle de bardoxolone ou d'analogues de ce dernier
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US11427533B2 (en)	2017-07-13	2022-08-30	Pliva Hrvatska D.O.O.	Crystalline polymorphs of bardoxolone methyl
US11708463B2 (en)	2018-04-06	2023-07-25	Capsugel Belgium Nv	Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
US11993574B2 (en)	2018-06-15	2024-05-28	Reata Pharmaceuticals, Inc	Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
WO2019246461A1 (fr)	2018-06-20	2019-12-26	Reata Pharmaceuticals, Inc.	Agonistes inverses dépendant de la cystéine de récepteurs nucléaires ror-gamma/ror-gamma-t et procédés de traitement de maladies ou de troubles associés
TW202038918A (zh)	2018-11-27	2020-11-01	日商協和麒麟股份有限公司	醫藥組合物
CN120248001A (zh)	2019-07-19	2025-07-04	里亚塔医药公司	C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
EP4146226A1 (fr)	2020-05-09	2023-03-15	Reata Pharmaceuticals Holdings, LLC	Procédés de traitement de la covid-19 à l'aide de méthyle de barbarrolone ou d'analogues de celui-ci
AU2021397631A1 (en)	2020-12-11	2023-07-20	Reata Pharmaceuticals Holdings, LLC	Synthetic triterpenoids for use in therapy
CN114558019A (zh) *	2022-03-26	2022-05-31	中国科学院昆明动物研究所	一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
US7435755B2 (en) *	2000-11-28	2008-10-14	The Trustees Of Dartmouth College	CDDO-compounds and combination therapies thereof
JP2008110962A (ja) *	2006-08-02	2008-05-15	Santen Pharmaceut Co Ltd	Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) *	2006-10-30	2009-08-19	ミツミ電機株式会社	カメラモジュール
JP2008247898A (ja) *	2007-03-08	2008-10-16	Santen Pharmaceut Co Ltd	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en)	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
ME03529B (fr)	2008-01-11	2020-04-20	Reata Pharmaceuticals Inc	Triterpénoïdes synthétiques et procédés d'utilisation dans le traitement de maladies
HUE035013T2 (en)	2009-02-13	2018-05-02	Reata Pharmaceuticals Inc	Delayed release, oral dosage compositions that contain amorphous cddo-me

2010
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/fr active Active
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Withdrawn
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 SM SM20190432T patent/SMT201900432T1/it unknown
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 CA CA2752048A patent/CA2752048C/fr active Active
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active Active
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/fr active Active
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 SM SM20170527T patent/SMT201700527T1/it unknown
- 2010-02-12 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/fr not_active Ceased
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
2017
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown

Also Published As

Publication number	Publication date
SI3254675T1 (sl)	2019-08-30
KR20140016441A (ko)	2014-02-07
CA2752048A1 (fr)	2010-08-19
HK1220130A1 (zh)	2017-04-28
US20140235711A1 (en)	2014-08-21
HRP20171639T1 (hr)	2017-12-15
PT3254675T (pt)	2019-06-14
US20120022156A1 (en)	2012-01-26
AU2010213594B2 (en)	2013-11-14
HUE035013T2 (en)	2018-05-02
JP5775464B2 (ja)	2015-09-09
SG173601A1 (en)	2011-09-29
WO2010093944A2 (fr)	2010-08-19
EP2395979B1 (fr)	2017-08-23
HUE044005T2 (hu)	2019-09-30
AU2010213594A1 (en)	2011-08-18
TR201909743T4 (tr)	2019-07-22
BRPI1008023B8 (pt)	2023-04-11
CN105232471A (zh)	2016-01-13
CY1122066T1 (el)	2020-11-25
PL3254675T3 (pl)	2019-09-30
EP2395979A2 (fr)	2011-12-21
NO2395979T3 (fr)	2018-01-20
LT2395979T (lt)	2017-12-11
EA023652B1 (ru)	2016-06-30
DK3254675T3 (da)	2019-06-24
CO6361904A2 (es)	2012-01-20
KR101483203B1 (ko)	2015-01-15
US8747901B2 (en)	2014-06-10
KR20110118721A (ko)	2011-10-31
ES2646816T3 (es)	2017-12-18
WO2010093944A3 (fr)	2011-08-11
EP3254675A1 (fr)	2017-12-13
DK2395979T3 (da)	2017-11-27
HRP20191092T1 (hr)	2019-11-29
US9155721B2 (en)	2015-10-13
JP2012518008A (ja)	2012-08-09
SMT201900432T1 (it)	2019-09-09
EP3254675B1 (fr)	2019-05-15
MY173715A (en)	2020-02-18
CA2752048C (fr)	2014-11-25
CY1119595T1 (el)	2018-03-07
BRPI1008023B1 (pt)	2019-12-31
LT3254675T (lt)	2019-06-25
SMT201700527T1 (it)	2018-01-11
IL214258A (en)	2017-06-29
NZ594488A (en)	2013-10-25
MX2011008344A (es)	2011-09-29
ZA201105630B (en)	2012-04-25
EA201190092A1 (ru)	2012-02-28
PL2395979T3 (pl)	2018-02-28
SI2395979T1 (sl)	2017-12-29
CN102387789A (zh)	2012-03-21
IL214258A0 (en)	2011-09-27
PT2395979T (pt)	2017-11-16
BRPI1008023A2 (pt)	2016-03-15

Publication	Publication Date	Title
ES2731601T3 (es)	2019-11-18	Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
US20250144112A1 (en)	2025-05-08	Suspension for oral administration comprising amorphous tolvaptan
TWI673051B (zh)	2019-10-01	恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
ES2946735T3 (es)	2023-07-25	Composición farmacéutica de dasatinib
Sheraz et al.	2016	Formulations of amlodipine: a review
JP2020518611A (ja)	2020-06-25	水溶解度及びバイオアベイラビリティが改善された組成物
US20200078377A1 (en)	2020-03-12	Pharmaceutical composition containing celecoxib
JP2012031164A (ja)	2012-02-16	フィルム状製剤
ES2868228T3 (es)	2021-10-21	Formas de dosificación farmacéuticas que contienen 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio
TW200423972A (en)	2004-11-16	Tablet having improved solubility
JP2024528736A (ja)	2024-07-30	パゾパニブ経口医薬組成物、その製造方法及び応用
HK1158988B (en)	2018-04-27	Delayed release, oral dosage compositions that contain amorphous cddo-me
HK1158988A (en)	2012-07-27	Delayed release, oral dosage compositions that contain amorphous cddo-me
BRPI0607372B1 (pt)	2019-04-30	Medicamento destinado à administração oral, compreendendo um inibidor da ciclooxigenase-2, e método de preparação do mesmo
HK1216620B (en)	2019-11-22	Suspension for oral administration comprising amorphous tolvaptan